Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07319598 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Test Tetrandrine Tablets for Connective Tissue Disease-Related Lung Disease

StatusRecruiting
PhasePhase 4
Started2023-11-02
View on ClinicalTrials.gov ↗
This study evaluates the efficacy and safety of tetrandrine tablets (60 mg, three times daily) compared to placebo in adult patients with connective tissue disease-related interstitial lung disease. Patients receive standard treatment (glucocorticoids and immunosuppressants) alongside the study drug or placebo for 24 weeks. The study measures changes in lung function, inflammatory markers, lung imaging, quality of life, and safety outcomes.
Trial Details
NCT Number NCT07319598
Lead Sponsor Peking University Third Hospital
Conditions Interstitial Lung Disease (ILD), Connective Tissue Disease-associated Interstitial Lung Disease
Enrollment 100 participants
Start Date 2023-11-02
Primary Completion 2026-10-15 (estimated)
Study Completion 2027-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-06